Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2026-09-04
DOI
https://doi.org/10.1126/sciadv.aei1190
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer

Obi L. Griffith, Nancy B. Myers, Binghan Yan, Ian S. Hagemann et al.
Science Advances
Immunotherapy and Immune Responses
article

Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer

Obi L. Griffith, Nancy B. Myers, Binghan Yan, Ian S. Hagemann, Lijin Li, Andrea Wang‐Gillam, Timothy P. Fleming, Feng Gao, Marianna B. Ruzinova, S. Peter Goedegebuure, Stephanie Myles, Daniel A. Laheru, Malachi Griffith, Carlos Parra-López, J. Li, John M. Herndon, Roheena Z. Panni, Elizabeth M. Jaffee, William G. Hawkins, William E. Gillanders, Julia W. Angkeow, Sherri R. Davies, Carl J. DeSelm, Kian‐Huat Lim, Robert D. Schreiber, Yilin Yang, Christopher A. Miller, Rashmi Mishra, Kartik Singhal, Yik Y. L. Yu, Darren Cullinan, Tammi Vickery, Felicia Zhang Perkins, Shelby Namen, Dominic Sanford, Xiuli Zhang
article en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.

Science AdvancesVol. 12(36)
James S. McDonnell Foundation (US), Barnes-Jewish Hospital (US), St. Joseph's Hospital and Medical Center (US), Medical University of South Carolina (US), Washington University in St. Louis (US), Universidad Nacional de Colombia (CO), Jewish Hospital (US), Sidney Kimmel Cancer Center (US), St. Joseph's Hospital (US), Sidney Kimmel Comprehensive Cancer Center (US)
Lustgarten Foundation, Foundation for Barnes-Jewish Hospital, Alvin J. Siteman Cancer Center, Centene Corporation, National Cancer Institute, National Institute of General Medical Sciences, UNICO Foundation
Good health and well-being
Openalex Percentile: Top 17%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.